Table 2.
Correlation between HDAC6 expression and DLBCL clinic-pathological features, cases (%)
| Clinical features | Low-expression group (n=39) | High-expression group (n=93) | χ2 value | P-value |
|---|---|---|---|---|
| Sex | 0.004 | 0.951 | ||
| Male | 22 (56.4) | 53 (57) | ||
| Female | 17 (43.6) | 40 (43) | ||
| Age (years) | 0.318 | 0.573 | ||
| ≤60 | 24 (61.5) | 62 (66.7) | ||
| >60 | 15 (38.5) | 31 (33.3) | ||
| Ann Arbor stage | 0.63 | 0.427 | ||
| I/II | 21 (53.8) | 57 (61.3) | ||
| III/IV | 18 (46.2) | 36 (38.7) | ||
| IPI score | 6.584 | 0.01 | ||
| 0–2 scores | 19 (48.7) | 67 (72) | ||
| 3–5 scores | 20 (51.3) | 26 (28) | ||
| ECOG score | 0.007 | 0.933 | ||
| <2 scores | 35 (89.7) | 83 (89.2) | ||
| ≥2 scores | 4 (10.3) | 10 (10.8) | ||
| B2-microglobulin | 7.376 | 0.007 | ||
| Increase | 22 (56.4) | 29 (31.2) | ||
| Normal | 17 (43.6) | 64 (68.8) | ||
| LDH | 5.401 | 0.02 | ||
| Increase | 21 (53.8) | 30 (32.3) | ||
| Normal | 18 (46.2) | 63 (67.7) | ||
| B symptom | 2.114 | 0.146 | ||
| Yes | 15 (38.5) | 24 (25.8) | ||
| None | 24 (61.5) | 69 (74.2) | ||
| Immunophenotype | 0.486 | 0.486 | ||
| GCB | 13 (33.3) | 37 (39.8) | ||
| Non-GCB | 26 (66.7) | 56 (60.2) | ||
| Location | 0.004 | 0.951 | ||
| Inside primary node | 22 (56.4) | 53 (57) | ||
| Outside primary node | 17 (43.6) | 40 (43) | ||
| Therapy | 0.092 | 0.761 | ||
| CHOP | 25 (64.1) | 57 (61.3) | ||
| R-CHOP | 14 (35.9) | 36 (38.7) |
Abbreviations: DLBCL, diffuse large B-cell lymphoma; HDAC6, histone deacetylase 6; IPI, International Prognostic Index; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; GCB, germinal center B-cell-like; CHOP, cyclophosphamide, doxorubicine, vincristine, prednisone; R-CHOP, rituximab plus CHOP.